October 8, 2021
Via: Biopharm InternationalChemoCentryx, a biopharmaceutical company targeting the chemokine and chemoattractant systems, announced that FDA approved Tavenos (avacopan), an orally-administered selective complement 5a receptor inhibitor, on Oct. 8th, 2021. Avacopan was approved as an adjunctive treatment for adults with severe active anti-neutrophil […]
September 26, 2023
September 21, 2023
September 19, 2023
September 14, 2023
September 7, 2023
September 1, 2023
September 19, 2023
September 5, 2023